|
Synonyms: CC-220 | compound 6 [PMID: 28425720] | Zenbexus®
iberdomide is an approved drug
Compound class:
Synthetic organic
Comment: Iberdomide (CC-220) is a cereblon E3 ligase modulator (CELMoD) [3], that is functionally akin to the thalidomide analogue Immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide. It promotes ubiquitin-mediated degradation of the transcription factors of IKZF1 (Ikaros) and IKZF3 (Aiolos).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| CC-220 is a novel cereblon-binding immunomodulator [3], functionally akin to lenalidomide and pomalidomide. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Systemic lupus erythematosus |
Disease Ontology:
DOID:9074 OMIM: 152700 Orphanet: ORPHA536 |
Phase 2 clinical candidate for SLE- see NCT03161483 | |
| Multiple myeloma |
Disease Ontology:
DOID:9538 OMIM: 254500 |
Phase 1/2 clinical candidate for MM- see NCT03161483 | |